Edition:
United States

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

16.75USD
14 Dec 2017
Change (% chg)

$-1.07 (-6.00%)
Prev Close
$17.82
Open
$17.73
Day's High
$17.98
Day's Low
$16.50
Volume
106,111
Avg. Vol
--
52-wk High
$24.50
52-wk Low
$16.11

Latest Key Developments (Source: Significant Developments)

Deciphera Pharmaceuticals Q3 loss $5.85 per share​
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Deciphera Pharmaceuticals Inc : :Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights.Qtrly loss $5.85 per share​.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article

New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 05:12pm EDT 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing‍​.  Full Article

Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 04:05pm EDT 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC ‍​as of Oct 2 - SEC filing‍​.  Full Article

Deciphera Pharmaceuticals shares open 17.9 pct above IPO price in debut
Thursday, 28 Sep 2017 11:00am EDT 

Sept 28 (Reuters) - :Deciphera Pharmaceuticals shares open at $20.05 in debut on NASDAQ vs IPO price of $17 per share.  Full Article

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage: